{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:53:55Z","timestamp":1767851635518,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.eclinm.2023.102272","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T23:54:13Z","timestamp":1698105253000},"page":"102272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Clinician preferences on treatment of smoldering myeloma: a\u00a0cross-sectional survey"],"prefix":"10.1016","volume":"65","author":[{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2023.102272_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsdottir","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102272_bib2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple Myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102272_bib3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102272_bib4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2023.102272_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2022.05.041","article-title":"Survival in smouldering myeloma and symptomatic myeloma: is there an emerging Will Rogers phenomenon?","volume":"172","author":"Chakraborty","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2023.102272_bib6","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/bloodadvances.2023009658","article-title":"Is aggressive treatment of smoldering myeloma the path to curing myeloma?","volume":"7","author":"Chakraborty","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102272_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-022-00671-z","article-title":"Financial toxicity in hematological malignancies: a systematic review","volume":"12","author":"Ouchveridze","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102272_bib8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102272_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102272_bib10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.2021011670","article-title":"How I approach smoldering multiple myeloma","volume":"140","author":"Vaxman","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102272_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.18232","article-title":"Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage","volume":"199","author":"Wennmann","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102272_bib12","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/bjh.18102","article-title":"Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials","volume":"197","author":"Soomro","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2023.102272_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101910","article-title":"SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of \u2018biomarker-defined early multiple myeloma'-a systematic review with meta-analysis","volume":"58","author":"Ludwig","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102272_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","author":"Sorrig","year":"2016","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102272_bib15","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1080\/10428194.2021.1938032","article-title":"The landscape of trials for smoldering multiple myeloma: endpoints, trial\u00a0design, and lessons learnt","volume":"62","author":"Mohyuddin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102272_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102272_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102272_bib18","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1007\/s11606-021-06737-1","article-title":"A\u00a0consensus-based checklist for reporting of survey studies (CROSS)","volume":"36","author":"Sharma","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102272_bib19","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102272_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102272_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102272_bib22","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.eclinm.2023.102272_bib23","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102272_bib24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bjh.18634","article-title":"The promise and harms of screening for plasma cell dyscrasias","volume":"200","author":"Mohyuddin","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102272_bib25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102272_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41571-022-00665-7","article-title":"Overall survival as a primary end point in multiple myeloma trials","volume":"19","author":"Cliff","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102272_bib27","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102272_bib28","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102272_bib29","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:20:56Z","timestamp":1762899656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023004492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"alternative-id":["S2589537023004492"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102272","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinician preferences on treatment of smoldering myeloma: a\u00a0cross-sectional survey","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102272"}}